This article was originally published in The Tan Sheet
Executive SummaryLegislation introduced in the House May 9 would "require that pseudoephedrine be dispensed only upon a written prescription of a licensed practitioner," thereby making it harder for meth producers to acquire pseudoephedrine. Sponsored by Rep. Marion Berry (D-Ark.), the Methamphetamine Elimination Act of 2002 notes meth producers can easily purchase OTC drug ingredient from any retail store, and "efforts to reduce access to pseudoephedrine by [meth] producers, such as blister packaging and sales thresholds, have not been effective deterrents." Berry staffer says Congressman hopes to spark new debate on meth issue, receive more active participation from FDA. HR 4690 was referred to the Commerce committee...
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.